Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT06531447
PHASE2
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients
Sponsor: The National Center of Oncology, Azerbaijan
View on ClinicalTrials.gov
Summary
The goal of the study is to investigate of the prognostics and predictive role of TUBB3 expression in locally advanced breast cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2014-05
Completion Date
2027-05
Last Updated
2024-08-01
Healthy Volunteers
No
Conditions
Interventions
DRUG
Cisplatin
Every 21 days 6 cycles
DRUG
Gemcitabine
Every 21 days (First and 8th days) 6 cycles
DRUG
Doxorubicin
Every 21 days 4 cycles
DRUG
Cyclophosphamide
Every 21 days 4 cycles
DRUG
Paclitaxel
Every 21 days 4 cycles or once a week for 12 weeks
Locations (1)
Elchin Mansurov
Baku, Azerbaijan